Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more
Market Cap & Net Worth: Oncolytics Biotech Inc (ONCY)
Oncolytics Biotech Inc (NASDAQ:ONCY) has a market capitalization of $106.62 Million ($106.62 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18117 globally and #6793 in its home market, demonstrating a -6.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncolytics Biotech Inc's stock price $0.99 by its total outstanding shares 107606376 (107.61 Million).
Oncolytics Biotech Inc Market Cap History: 2015 to 2026
Oncolytics Biotech Inc's market capitalization history from 2015 to 2026. Data shows change from $274.95 Million to $106.62 Million (-12.85% CAGR).
Index Memberships
Oncolytics Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #496 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1681 of 3165 |
Weight: Oncolytics Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oncolytics Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncolytics Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ONCY by Market Capitalization
Companies near Oncolytics Biotech Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Oncolytics Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oncolytics Biotech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Oncolytics Biotech Inc's market cap moved from $274.95 Million to $ 106.62 Million, with a yearly change of -12.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $106.62 Million | +13.36% |
| 2025 | $94.05 Million | -4.36% |
| 2024 | $98.33 Million | -32.31% |
| 2023 | $145.27 Million | -17.18% |
| 2022 | $175.40 Million | +17.27% |
| 2021 | $149.57 Million | -41.60% |
| 2020 | $256.10 Million | -50.00% |
| 2019 | $512.21 Million | +162.98% |
| 2018 | $194.77 Million | -66.46% |
| 2017 | $580.74 Million | +173.52% |
| 2016 | $212.32 Million | -22.78% |
| 2015 | $274.95 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Oncolytics Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $106.62 Million USD |
| MoneyControl | $106.62 Million USD |
| MarketWatch | $106.62 Million USD |
| marketcap.company | $106.62 Million USD |
| Reuters | $106.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.